Risk Assets continue to struggle despite some gains in the S&P 500 and Dow Jones. It highlights investor concerns about US ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

Retinoic acid receptor alpha (RARα) is a nuclear receptor with a central role in spermatogenesis. Genetic knockout studies in mice have shown that the lack of RARα leads to a complete absence of sperm ...

The Alpha release of IOTA Identity brings self-sovereign identity, verifiable credentials, and privacy-first digital ...

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They ...

Machine learning excels at quantitative analysis, but humans still rank in leadership and adapting to unprecedented market ...

Why Active Quant? Active Quant provides a structured, research-backed approach designed to systematically capture market inefficiencies. It integrates insights from both traditional factors (such as ...

Upon listing, Alpha Data’s market capitalisation stood at approximately Dhs1.5bn, reinforcing its strong position in the ...

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

This manuscript addresses the role of alpha oscillations in sensory gain control. The authors use an attention-cuing task in an initial EEG study followed by a separate MEG replication study to ...

Alpha Data's will be UAE first IPO of 2025 and with lots more of action Alpha Data is coming to ADX, and as most market analysts had expected, set the IPO price at the top of the range.

Alpha Data, the technology services company that plans to sell 400 million shares in an Abu Dhabi IPO, has priced the offer at 1.50 dirhams ($0.41) per share, the top end of the indicated range, on ...